Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

After-Hours Movers: Nautilus Gains on Strategic Review

Published 09/26/2022, 05:44 PM
Updated 09/26/2022, 05:46 PM
© Reuters.  After-Hours Movers: Nautilus Gains on Strategic Review

© Reuters. After-Hours Movers: Nautilus Gains on Strategic Review

After-Hours Stock Movers:

9 Meters Biopharma Inc (NASDAQ:NMTR42% HIGHER; announced today positive final results from the Phase 2 study of vurolenatide and the outcome from its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). Vurolenatide is a proprietary long-acting GLP-1 receptor agonist in development for adults with short bowel syndrome (SBS). Based on the outcome from the meeting and the Phase 2 data, 9 Meters intends to finalize the Phase 3 protocol in collaboration with the FDA during the fourth quarter. Clinical plans and activities are currently underway to facilitate initiation of the study upon protocol finalization. The company plans to provide further details on the Phase 3 vurolenatide clinical development program following protocol finalization.

Nautilus Group Inc (NYSE:NLS) 6% HIGHER; announced that its Board launched a comprehensive review of strategic alternatives, which may include a potential sale of the company, to identify opportunities to accelerate the companys digital transformation under its previously announced North Star plan and enhance shareholder value.

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) 5% HIGHER; announced that the IND application to initiate a Phase 1/1b clinical trial of mupadolimab (formerly CPI-006) has been approved by the Center for Drug Evaluation of the China National Medical Products Administration. The study will be conducted by Angel Pharmaceuticals Ltd. (Angel Pharma), Corvus' partner in China. Mupadolimab is a humanized monoclonal antibody designed to be directed against CD73 with a proposed unique mechanism of activating B cells to generate immune responses to tumor antigens and viruses, in patients with relapsed refractory non-small cell lung cancer (NSCLC) and head and neck squamous cell cancers (HNSCC).

Exicure (NASDAQ:XCUR) 5% HIGHER; announced plans to restructure the company and align resources to continue exploring strategic alternatives that maximize stockholder value

Splunk (NASDAQ:SPLK) 3% HIGHER; announced that Jason Child, Splunks CFO since 2019, has accepted a position at a leading pre-IPO semiconductor company. Reaffirms outlook.

VOXX International Corporation (NASDAQ:VOXX) 1% HIGHER; President & CEO, Patrick Lavelle, bought 13,500 shares on 09/23/22 at $6.8167.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.